• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Conference on Cognitive Sciences, Genomics and Bioinformatics >Investigation of the Allergenic Properties of the Interferon-Lambda 1, Pegylated by Electron-Beam Method
【24h】

Investigation of the Allergenic Properties of the Interferon-Lambda 1, Pegylated by Electron-Beam Method

机译：电子束法研究聚乙二醇化干扰素-λ1的致敏特性

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The development of effective antiviral drugs for use in ophthalmic practice is an urgent task of modern medicine. Type III interferons have similar functions with well-known type I interferons, that is they have antiviral, antitumor and immunomodulating activities. However, their receptors are expressed primarily on epithelial barrier cells, such as mucous membranes. In this regard, type III interferons have less systemic side effects when used for therapeutic purposes. However, interferons are protein molecules, which mean that they are practically not absorbed from gastrointestinal tract, therefore, they need parenteral administration, which reduces patient compliance.It was shown that electron-beam pegylation increases the solubility of the original substances, reduces immunogenic properties, and also increases the oral bioavailability of proteins up to 20%. However, a change of the molecule structure can significantly change both pharmacokinetic and pharmacodynamic properties.In this work the allergenic properties of interferon-1, pegylated by electron beam method, were investigated in the systemic anaphylaxis reaction in guinea pigs, and in the active cutaneous anaphylaxis reaction and the conjunctival test in mice.Thus, it was found that pegylated IFN-λ1, obtained by the electron beam method, generally does not have allergenic properties when used in a therapeutic dose or in ten-fold higher dose, in the conditions of the experiments. This creates the prerequisites for the development of a drug based on pegylated IFN-λ1 for the treatment of viral infections of the ocular surface, and it requires further experiments to establish its effectiveness.
机译：开发用于眼科实践的有效抗病毒药物是现代医学的紧迫任务。 III型干扰素与众所周知的I型干扰素具有相似的功能，即它们具有抗病毒，抗肿瘤和免疫调节活性。然而，它们的受体主要在上皮屏障细胞如粘膜上表达。就这一点而言，当用于治疗目的时，III型干扰素具有较小的全身性副作用。然而，干扰素是蛋白质分子，这意味着它们实际上不会从胃肠道吸收，因此，它们需要肠胃外给药，从而降低了患者的依从性。研究表明，电子束聚乙二醇化会增加原始物质的溶解度，降低免疫原性。 ，还可以使蛋白质的口服生物利用度提高多达20％。然而，分子结构的改变可以显着改变药代动力学和药效学性质。在这项工作中，研究了通过电子束法聚乙二醇化的干扰素-1的过敏原性质，其在豚鼠的全身过敏反应和活性皮肤中得到了研究。小鼠的过敏反应和结膜试验。因此，发现在一定条件下，以电子束方法获得的聚乙二醇化IFN-λ1通常在治疗剂量或高十倍剂量时不具有变应原性。实验。这为开发基于聚乙二醇化IFN-λ1的药物治疗眼表病毒感染创造了先决条件，还需要进一步的实验来确定其有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号